Novel Neuroprotective, or ARG-007 is a drug to protect the brain following an injury, such as stroke or another significant event. It aims to reduce cell decrement when administered via IV immediately post-event, and prior assessment in hospital.
This potentially reduces the impact flow on complications such as the ability to walk or talk. 15M people suffer stroke globally per annum and 90% have associated functional impairment.
The drug potential is not solely related to stroke and has potential for success in post-natal as a result of difficult birth which limited oxygen supply.
Traumatic brain injury from concussion has also been evaluated, however, note for below, the main thrust is for stroke.
Scientific validation is a long process and Argenica is no different. This development is a decade-long project to get to the stage of phase one clinical trials – testing on healthy human volunteers. The trial will be conducted over 4 groups of 8 pax over 8 days which means trial results will be available in the next few months.
Phase two will be on stroke patients in hospital emergency departments. This will again be a validation of safety of the patient.
Phase three is hundreds or thousands of patients across multiple sites.
Cash burn is much lower than I anticipated but will step when trials commence.
And with any of these “if” is the million-dollar question, if trials are successful, this has the potential to go to da moon.
